Actively Recruiting
Evaluating KarXT Versus Placebo for Treating Manic Episodes in Bipolar-I Disorder During a 3-Week Inpatient Period
Led by Bristol-Myers Squibb · Updated on 2026-10-23
274
Participants Needed
74
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of KarXT for treating manic episodes in adults with Bipolar-I Disorder. This Phase 3, randomized, double-blind, placebo-controlled study focuses on adults experiencing an acute episode of mania or mania with mixed features. The study aims to compare KarXT to placebo during a 3-week inpatient treatment period to assess symptom improvement. Participants will be randomly assigned to receive either KarXT or a placebo with flexible dosing during the 3-week inpatient phase. Prior to treatment, participants must undergo a screening period and psychotropic medications must be washed out within 14 days before starting. After the treatment phase, there is a safety follow-up period, with the entire study lasting no more than seven weeks. During the study, participants will be hospitalized for close monitoring. Researchers will assess symptoms using the Young Mania Rating Scale and Clinical Global Impressions-Bipolar at baseline and week 3. Safety evaluations will continue through follow-up visits. The main outcome is the change in mania symptoms after 3 weeks of treatment, with additional measures of clinical response and safety observed throughout the study.
CONDITIONS
Brief Title
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder
Research Team
B
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
F
First line of the email MUST contain NCT # and Site #.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here